歐洲、中東、非洲的腦膜炎診斷檢驗市場:產業分析,市場規模、佔有率、成長、趨勢、預測 (2021年~2031年)
市場調查報告書
商品編碼
1067921

歐洲、中東、非洲的腦膜炎診斷檢驗市場:產業分析,市場規模、佔有率、成長、趨勢、預測 (2021年~2031年)

Meningitis Diagnostic Testing Market - Europe and Middle East & Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

出版日期: | 出版商: Transparency Market Research | 英文 281 Pages | 商品交期: 2-10個工作天內

價格

本報告提供歐洲、中東、非洲的腦膜炎診斷檢驗的市場相關分析,近來的成長趨勢和今後的市場機會,市場規模的成果值 (2017年~2020年) 和預測值 (2021年~2031年),在預測期間內的成長率預測等調查。

目錄

第1章 序文

第2章 假設調查手法

第3章 摘要整理:歐洲、中東、非洲的腦膜炎診斷檢驗市場

第4章 市場概要

  • 簡介
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 歐洲、中東、非洲的腦膜炎診斷檢驗市場分析與預測 (2017年~2031年)
    • 市場收益的預測 (單位:100萬美元)

第5章 主要考察

  • 大企業的主要的成功因素
  • 新型冠狀病毒感染疾病 (COVID-19) 感染擴大:對產業的影響 (價值鏈及短期/中期/長期的影響)
  • 產業的主要趨勢 (產品銷售,產品核可,事業擴大等)
  • 法規情境

第6章 歐洲、中東、非洲的腦膜炎診斷檢驗市場分析與預測:各產品

第7章 歐洲、中東、非洲的腦膜炎診斷檢驗市場分析與預測:各類型

第8章 歐洲、中東、非洲的腦膜炎診斷檢驗市場分析與預測:各終端用戶

第9章 歐洲、中東、非洲的腦膜炎診斷檢驗市場分析與預測:各地區

第10章 歐洲的腦膜炎診斷檢驗市場分析與預測

第11章 中東、非洲的腦膜炎診斷檢驗市場分析與預測

第12章 競爭情形

  • 企業簡介
    • Thermo Fisher Scientific, Inc.
    • BioFire Diagnostics
    • Fast Track Diagnostics Ltd. (FTD) - Siemens Healthineers
    • Bio-Rad Laboratories, Inc.
    • IMMY
    • Nanosphere (Luminex Corporation)
    • Seegene, Inc.
    • Qnostics
    • ELITechGroup
    • Abbott Laboratories
    • 其他企業
Product Code: TMRGL84238

Scope of the Report

TMR's report on the meningitis diagnostic testing market in EMEA studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the meningitis diagnostic testing market in EMEA for the period 2017-2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the meningitis diagnostic testing market in EMEA from 2021 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the meningitis diagnostic testing market in EMEA.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the meningitis diagnostic testing market in EMEA.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the meningitis diagnostic testing market in EMEA. These serve as valuable tools for existing market players as well as for entities interested in participating in the meningitis diagnostic testing market in EMEA.

The report delves into the competition landscape of the meningitis diagnostic testing market in EMEA. Key players operating in the meningitis diagnostic testing market in EMEA have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the meningitis diagnostic testing market in EMEA profiled in this report.

Key Questions Answered:

  • What is the sales/revenue generated by meningitis diagnostic testing across all regions during the forecast period?
  • What are the opportunities in the meningitis diagnostic testing market in EMEA?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue in EMEA market in 2031?
  • Which segment is likely to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in EMEA market?

Research Objectives and Research Approach

The comprehensive report on the meningitis diagnostic testing market in EMEA begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments are visually appealing to readers. This allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the meningitis diagnostic testing market in EMEA in terms of product type, panel type, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the meningitis diagnostic testing market in EMEA.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Europe and Middle East & Africa Meningitis Diagnostic Testing Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Market Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Key Success Factors for Top Players
  • 5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid /long term impact)
  • 5.3. Key Industry Developments (product launch, product approvals, business expansion, etc.)
  • 5.4. Regulatory Scenario

6. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, By Product, 2017-2031
    • 6.3.1. Latex Agglutination Tests
    • 6.3.2. Lateral Flow Assay
    • 6.3.3. PCR Assay
    • 6.3.4. ELISA Tests
    • 6.3.5. Culture Test
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, By Product

7. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Type, 2017-2031
    • 7.3.1. Syndromic Full Multiplex Panel
    • 7.3.2. Low Plex Panel
  • 7.4. Market Attractiveness Analysis, By Type

8. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, By End-user, 2017-2031
  • 8.4. Market Attractiveness Analysis, By End-user

9. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, By Region

10. Europe Meningitis Diagnostic Testing Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, By Product, 2017-2031
    • 10.2.1. Latex Agglutination Tests
    • 10.2.2. Lateral Flow Assay
    • 10.2.3. PCR Assay
    • 10.2.4. ELISA Tests
    • 10.2.5. Culture Test
    • 10.2.6. Others
  • 10.3. Market Value Forecast, By Type, 2017-2031
    • 10.3.1. Syndromic Full Multiplex Panel
    • 10.3.2. Low Plex Panel
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Hospitals
    • 10.4.2. Diagnostic Centers
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. Germany
      • 10.5.1.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.1.1.1. Latex Agglutination Tests
        • 10.5.1.1.2. Lateral Flow Assay
        • 10.5.1.1.3. PCR Assay
        • 10.5.1.1.4. ELISA Tests
        • 10.5.1.1.5. Culture Test
        • 10.5.1.1.6. Others
      • 10.5.1.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.1.2.1. Syndromic Full Multiplex Panel
        • 10.5.1.2.2. Low Plex Panel
      • 10.5.1.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.1.3.1. Hospitals
        • 10.5.1.3.2. Diagnostic Centers
        • 10.5.1.3.3. Others
    • 10.5.2. U.K.
      • 10.5.2.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.2.1.1. Latex Agglutination Tests
        • 10.5.2.1.2. Lateral Flow Assay
        • 10.5.2.1.3. PCR Assay
        • 10.5.2.1.4. ELISA Tests
        • 10.5.2.1.5. Culture Test
        • 10.5.2.1.6. Others
      • 10.5.2.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.2.2.1. Syndromic Full Multiplex Panel
        • 10.5.2.2.2. Low Plex Panel
      • 10.5.2.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.2.3.1. Hospitals
        • 10.5.2.3.2. Diagnostic Centers
        • 10.5.2.3.3. Others
    • 10.5.3. France
      • 10.5.3.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.3.1.1. Latex Agglutination Tests
        • 10.5.3.1.2. Lateral Flow Assay
        • 10.5.3.1.3. PCR Assay
        • 10.5.3.1.4. ELISA Tests
        • 10.5.3.1.5. Culture Test
        • 10.5.3.1.6. Others
      • 10.5.3.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.3.2.1. Syndromic Full Multiplex Panel
        • 10.5.3.2.2. Low Plex Panel
      • 10.5.3.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.3.3.1. Hospitals
        • 10.5.3.3.2. Diagnostic Centers
        • 10.5.3.3.3. Others
    • 10.5.4. Italy
      • 10.5.4.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.4.1.1. Latex Agglutination Tests
        • 10.5.4.1.2. Lateral Flow Assay
        • 10.5.4.1.3. PCR Assay
        • 10.5.4.1.4. ELISA Tests
        • 10.5.4.1.5. Culture Test
        • 10.5.4.1.6. Others
      • 10.5.4.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.4.2.1. Syndromic Full Multiplex Panel
        • 10.5.4.2.2. Low Plex Panel
      • 10.5.4.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.4.3.1. Hospitals
        • 10.5.4.3.2. Diagnostic Centers
        • 10.5.4.3.3. Others
    • 10.5.5. Spain
      • 10.5.5.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.5.1.1. Latex Agglutination Tests
        • 10.5.5.1.2. Lateral Flow Assay
        • 10.5.5.1.3. PCR Assay
        • 10.5.5.1.4. ELISA Tests
        • 10.5.5.1.5. Culture Test
        • 10.5.5.1.6. Others
      • 10.5.5.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.5.2.1. Syndromic Full Multiplex Panel
        • 10.5.5.2.2. Low Plex Panel
      • 10.5.5.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.5.3.1. Hospitals
        • 10.5.5.3.2. Diagnostic Centers
        • 10.5.5.3.3. Others
    • 10.5.6. Benelux
      • 10.5.6.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.6.1.1. Latex Agglutination Tests
        • 10.5.6.1.2. Lateral Flow Assay
        • 10.5.6.1.3. PCR Assay
        • 10.5.6.1.4. ELISA Tests
        • 10.5.6.1.5. Culture Test
        • 10.5.6.1.6. Others
      • 10.5.6.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.6.2.1. Syndromic Full Multiplex Panel
        • 10.5.6.2.2. Low Plex Panel
      • 10.5.6.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.6.3.1. Hospitals
        • 10.5.6.3.2. Diagnostic Centers
        • 10.5.6.3.3. Others
    • 10.5.7. Poland
      • 10.5.7.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.7.1.1. Latex Agglutination Tests
        • 10.5.7.1.2. Lateral Flow Assay
        • 10.5.7.1.3. PCR Assay
        • 10.5.7.1.4. ELISA Tests
        • 10.5.7.1.5. Culture Test
        • 10.5.7.1.6. Others
      • 10.5.7.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.7.2.1. Syndromic Full Multiplex Panel
        • 10.5.7.2.2. Low Plex Panel
      • 10.5.7.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.7.3.1. Hospitals
        • 10.5.7.3.2. Diagnostic Centers
        • 10.5.7.3.3. Others
    • 10.5.8. Norway
      • 10.5.8.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.8.1.1. Latex Agglutination Tests
        • 10.5.8.1.2. Lateral Flow Assay
        • 10.5.8.1.3. PCR Assay
        • 10.5.8.1.4. ELISA Tests
        • 10.5.8.1.5. Culture Test
        • 10.5.8.1.6. Others
      • 10.5.8.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.8.2.1. Syndromic Full Multiplex Panel
        • 10.5.8.2.2. Low Plex Panel
      • 10.5.8.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.8.3.1. Hospitals
        • 10.5.8.3.2. Diagnostic Centers
        • 10.5.8.3.3. Others
    • 10.5.9. Sweden
      • 10.5.9.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.9.1.1. Latex Agglutination Tests
        • 10.5.9.1.2. Lateral Flow Assay
        • 10.5.9.1.3. PCR Assay
        • 10.5.9.1.4. ELISA Tests
        • 10.5.9.1.5. Culture Test
        • 10.5.9.1.6. Others
      • 10.5.9.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.9.2.1. Syndromic Full Multiplex Panel
        • 10.5.9.2.2. Low Plex Panel
      • 10.5.9.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.9.3.1. Hospitals
        • 10.5.9.3.2. Diagnostic Centers
        • 10.5.9.3.3. Others
    • 10.5.10. Denmark
      • 10.5.10.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.10.1.1. Latex Agglutination Tests
        • 10.5.10.1.2. Lateral Flow Assay
        • 10.5.10.1.3. PCR Assay
        • 10.5.10.1.4. ELISA Tests
        • 10.5.10.1.5. Culture Test
        • 10.5.10.1.6. Others
      • 10.5.10.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.10.2.1. Syndromic Full Multiplex Panel
        • 10.5.10.2.2. Low Plex Panel
      • 10.5.10.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.10.3.1. Hospitals
        • 10.5.10.3.2. Diagnostic Centers
        • 10.5.10.3.3. Others
    • 10.5.11. Finland
      • 10.5.11.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.11.1.1. Latex Agglutination Tests
        • 10.5.11.1.2. Lateral Flow Assay
        • 10.5.11.1.3. PCR Assay
        • 10.5.11.1.4. ELISA Tests
        • 10.5.11.1.5. Culture Test
        • 10.5.11.1.6. Others
      • 10.5.11.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.11.2.1. Syndromic Full Multiplex Panel
        • 10.5.11.2.2. Low Plex Panel
      • 10.5.11.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.11.3.1. Hospitals
        • 10.5.11.3.2. Diagnostic Centers
        • 10.5.11.3.3. Others
    • 10.5.12. Austria
      • 10.5.12.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.12.1.1. Latex Agglutination Tests
        • 10.5.12.1.2. Lateral Flow Assay
        • 10.5.12.1.3. PCR Assay
        • 10.5.12.1.4. ELISA Tests
        • 10.5.12.1.5. Culture Test
        • 10.5.12.1.6. Others
      • 10.5.12.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.12.2.1. Syndromic Full Multiplex Panel
        • 10.5.12.2.2. Low Plex Panel
      • 10.5.12.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.12.3.1. Hospitals
        • 10.5.12.3.2. Diagnostic Centers
        • 10.5.12.3.3. Others
    • 10.5.13. Switzerland
      • 10.5.13.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.13.1.1. Latex Agglutination Tests
        • 10.5.13.1.2. Lateral Flow Assay
        • 10.5.13.1.3. PCR Assay
        • 10.5.13.1.4. ELISA Tests
        • 10.5.13.1.5. Culture Test
        • 10.5.13.1.6. Others
      • 10.5.13.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.13.2.1. Syndromic Full Multiplex Panel
        • 10.5.13.2.2. Low Plex Panel
      • 10.5.13.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.13.3.1. Hospitals
        • 10.5.13.3.2. Diagnostic Centers
        • 10.5.13.3.3. Others
    • 10.5.14. Rest of Europe
      • 10.5.14.1. Market Value Forecast, by Product, 2017-2031
        • 10.5.14.1.1. Latex Agglutination Tests
        • 10.5.14.1.2. Lateral Flow Assay
        • 10.5.14.1.3. PCR Assay
        • 10.5.14.1.4. ELISA Tests
        • 10.5.14.1.5. Culture Test
        • 10.5.14.1.6. Others
      • 10.5.14.2. Market Value Forecast, by Type, 2017-2031
        • 10.5.14.2.1. Syndromic Full Multiplex Panel
        • 10.5.14.2.2. Low Plex Panel
      • 10.5.14.3. Market Value Forecast, by End-user, 2017-2031
        • 10.5.14.3.1. Hospitals
        • 10.5.14.3.2. Diagnostic Centers
        • 10.5.14.3.3. Others
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Product
    • 10.6.2. By Type
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Product, 2017-2031
    • 11.2.1. Latex Agglutination Tests
    • 11.2.2. Lateral Flow Assay
    • 11.2.3. PCR Assay
    • 11.2.4. ELISA Tests
    • 11.2.5. Culture Test
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by Type, 2017-2031
    • 11.3.1. Syndromic Full Multiplex Panel
    • 11.3.2. Low Plex Panel
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Hospitals
    • 11.4.2. Diagnostic Centers
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country, 2017-2031
    • 11.5.1. GCC Countries
      • 11.5.1.1. Market Value Forecast, by Product, 2017-2031
        • 11.5.1.1.1. Latex Agglutination Tests
        • 11.5.1.1.2. Lateral Flow Assay
        • 11.5.1.1.3. PCR Assay
        • 11.5.1.1.4. ELISA Tests
        • 11.5.1.1.5. Culture Test
        • 11.5.1.1.6. Others
      • 11.5.1.2. Market Value Forecast, by Type, 2017-2031
        • 11.5.1.2.1. Syndromic Full Multiplex Panel
        • 11.5.1.2.2. Low Plex Panel
      • 11.5.1.3. Market Value Forecast, by End-user, 2017-2031
        • 11.5.1.3.1. Hospitals
        • 11.5.1.3.2. Diagnostic Centers
        • 11.5.1.3.3. Others
    • 11.5.2. South Africa
      • 11.5.2.1. Market Value Forecast, by Product, 2017-2031
        • 11.5.2.1.1. Latex Agglutination Tests
        • 11.5.2.1.2. Lateral Flow Assay
        • 11.5.2.1.3. PCR Assay
        • 11.5.2.1.4. ELISA Tests
        • 11.5.2.1.5. Culture Test
        • 11.5.2.1.6. Others
      • 11.5.2.2. Market Value Forecast, by Type, 2017-2031
        • 11.5.2.2.1. Syndromic Full Multiplex Panel
        • 11.5.2.2.2. Low Plex Panel
      • 11.5.2.3. Market Value Forecast, by End-user, 2017-2031
        • 11.5.2.3.1. Hospitals
        • 11.5.2.3.2. Diagnostic Centers
        • 11.5.2.3.3. Others
    • 11.5.3. Rest of Middle East & Africa
      • 11.5.3.1. Market Value Forecast, by Product, 2017-2031
        • 11.5.3.1.1. Latex Agglutination Tests
        • 11.5.3.1.2. Lateral Flow Assay
        • 11.5.3.1.3. PCR Assay
        • 11.5.3.1.4. ELISA Tests
        • 11.5.3.1.5. Culture Test
        • 11.5.3.1.6. Others
      • 11.5.3.2. Market Value Forecast, by Type, 2017-2031
        • 11.5.3.2.1. Syndromic Full Multiplex Panel
        • 11.5.3.2.2. Low Plex Panel
      • 11.5.3.3. Market Value Forecast, by End-user, 2017-2031
        • 11.5.3.3.1. Hospitals
        • 11.5.3.3.2. Diagnostic Centers
        • 11.5.3.3.3. Others
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Product
    • 11.6.2. By Type
    • 11.6.3. By End-user
    • 11.6.4. By Country

12. Competition Landscape

  • 12.1. Company Profiles
    • 12.1.1. Thermo Fisher Scientific, Inc.
      • 12.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.1.2. Product Portfolio
      • 12.1.1.3. SWOT Analysis
      • 12.1.1.4. Strategic Overview
    • 12.1.2. BioFire Diagnostics
      • 12.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.2.2. Product Portfolio
      • 12.1.2.3. SWOT Analysis
      • 12.1.2.4. Strategic Overview
    • 12.1.3. Fast Track Diagnostics Ltd. (FTD) - Siemens Healthineers
      • 12.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.3.2. Product Portfolio
      • 12.1.3.3. SWOT Analysis
      • 12.1.3.4. Strategic Overview
    • 12.1.4. Bio-Rad Laboratories, Inc.
      • 12.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.4.2. Product Portfolio
      • 12.1.4.3. SWOT Analysis
      • 12.1.4.4. Strategic Overview
    • 12.1.5. IMMY
      • 12.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.5.2. Product Portfolio
      • 12.1.5.3. SWOT Analysis
      • 12.1.5.4. Strategic Overview
    • 12.1.6. Nanosphere (Luminex Corporation)
      • 12.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.6.2. Product Portfolio
      • 12.1.6.3. SWOT Analysis
      • 12.1.6.4. Strategic Overview
    • 12.1.7. Seegene, Inc.
      • 12.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.7.2. Product Portfolio
      • 12.1.7.3. SWOT Analysis
      • 12.1.7.4. Strategic Overview
    • 12.1.8. Qnostics
      • 12.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.8.2. Product Portfolio
      • 12.1.8.3. SWOT Analysis
      • 12.1.8.4. Strategic Overview
    • 12.1.9. ELITechGroup
      • 12.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.9.2. Product Portfolio
      • 12.1.9.3. SWOT Analysis
      • 12.1.9.4. Strategic Overview
    • 12.1.10. Abbott Laboratories
      • 12.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 12.1.10.2. Product Portfolio
      • 12.1.10.3. SWOT Analysis
      • 12.1.10.4. Strategic Overview
    • 12.1.11. Other Prominent Players

List of Table

  • Table 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 06: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 07: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-User, 2017-2031
  • Table 08: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 10: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 11: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 12: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 13: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 14: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 15: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 16: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 17: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 18: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 19: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 20: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 22: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 23: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 24: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 25: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 26: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 27: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 28: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 29: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 30: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 31: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 32: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 33: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 34: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 35: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 36: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 37: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 38: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 39: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 40: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 41: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 42: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 43: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 44: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 45: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 46: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 47: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 48: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 49: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 50: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 51: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 52: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 53: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 54: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 55: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 56: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 57: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 58: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 59: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 60: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 61: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 62: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017-2031
  • Table 63: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figure

  • Figure 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Product Type (2020)
  • Figure 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by End-user (2020)
  • Figure 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Panel Type (2020)
  • Figure 05: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share, by Region (2020)
  • Figure 06: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 07: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Latex Agglutination Tests, 2017-2031
  • Figure 08: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Lateral Flow Assay, 2017-2031
  • Figure 09: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by PCR Assay, 2017-2031
  • Figure 10: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by ELISA Tests, 2017-2031
  • Figure 11: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Culture Test, 2017-2031
  • Figure 12: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by others, 2017-2031
  • Figure 13: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 14: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 15: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Syndromic Full Multiplex Panel, 2017-2031
  • Figure 16: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Low Plex Panel, 2017-2031
  • Figure 17: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 18: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 19: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Hospitals, 2017-2031
  • Figure 20: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Diagnostic Centers, 2017-2031
  • Figure 21: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 22: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 23: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Region, 2020 and 2031
  • Figure 24: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Region, 2021-2031
  • Figure 25: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 26: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 27: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 28: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 29: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-User, 2020 and 2031
  • Figure 30: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-User, 2021-2031
  • Figure 31: Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Country, 2020 and 2031
  • Figure 32: Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country, 2021-2031
  • Figure 33: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 34: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 35: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 36: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 37: Germany Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 38: Germany Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 39: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 40: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 41: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 42: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 43: U.K. Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 44: U.K. Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 45: France Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 46: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 47: France Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 48: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 49: France Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 50: France Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 51: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 52: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 53: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 54: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 55: Italy Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 56: Italy Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 57: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 58: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 59: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 60: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 61: Spain Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 62: Spain Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 63: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 64: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 65: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 66: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 67: Benelux Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 68: Benelux Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 69: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 70: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 71: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 72: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 73: Poland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 74: Poland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 75: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 76: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 77: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 78: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 79: Norway Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 80: Norway Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 81: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 82: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 83: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 84: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 85: Sweden Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 86: Sweden Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 87: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 88: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 89: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 90: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 91: Denmark Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 92: Denmark Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 93: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 94: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 95: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 96: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 97: Finland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 98: Finland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 99: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 100: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 101: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 102: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 103: Austria Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 104: Austria Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 105: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 106: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 107: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 108: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 109: Switzerland Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 110: Switzerland Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 111: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 112: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 113: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 114: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 115: Rest of Europe Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 116: Rest of Europe Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 117: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 118: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 119: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 120: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 121: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 122: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 123: Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
  • Figure 124: Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 125: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 126: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 127: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 128: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 129: GCC Countries Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 130: GCC Countries Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 131: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 132: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 133: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 134: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 135: South Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 136: South Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 137: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Product Type, 2020 and 2031
  • Figure 138: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Product Type, 2021-2031
  • Figure 139: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by Panel Type, 2020 and 2031
  • Figure 140: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by Panel Type, 2021-2031
  • Figure 141: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 142: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Attractiveness Analysis, by End-user, 2021-2031